Entry Point Capital, LLC Incyte Corp Call Options Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INCY
# of Institutions
644Shares Held
186MCall Options Held
714KPut Options Held
557K-
Baker Bros. Advisors LP New York, NY30.7MShares$2.29 Billion21.76% of portfolio
-
Black Rock Inc. New York, NY21.4MShares$1.59 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA20.4MShares$1.52 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA15.3MShares$1.14 Billion0.61% of portfolio
-
State Street Corp Boston, MA10.6MShares$787 Million0.03% of portfolio
About INCYTE CORP
- Ticker INCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 222,431,008
- Market Cap $16.6B
- Description
- Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...